Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeoAg-mBRAF
- Development stage
- Unknown
- Lead developer
- University of Virginia
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
NeoAg-mBRAF is a synthetic peptide vaccine component representing a shared mutated BRAF-V600E neoantigen. It consists of a 30-amino acid peptide (BRAF 585–614) containing the V600E mutation, with an added N-terminal histidine to facilitate MHC class II restriction. Developed by Craig L. Slingluff, Jr. at the University of Virginia, it is being investigated as part of a multi-component immunotherapy regimen (Mel66 trial) that includes six nonmutated melanoma-specific helper peptides (6MHP), the TLR3 agonist polyICLC, and the CD40-activating antibody CDX-1140. The vaccine aims to stimulate CD4+ T cell immune responses against the BRAF V600E neoantigen in patients with high-risk cutaneous or uveal melanoma in the adjuvant setting.
- Other names
- BRAF585-614-V600EBRAF-585-614-V600EBRAF 585-614-V600Emutated BRAF-V600E neoantigen peptide
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on NeoAg-mBRAF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoAg-mBRAF.